Merck Patent Gmbh

Eberhard-karls-universitaet Tuebingen Universitaetsklinikum

Phillipp Lang

Florian Lang

Norbert Beier

Rolf Gericke

Thomas Fuchss

Karl Lang

Hannsjoerg Seybert

Nikola Jeck

Siegfried Waldegger

Angelika Lampert

The present invention relates to a compound of formulas I, Ia, Ib and II, wherein R1 to R11 are herein defined.

SGK1 inhibitors for the prophylaxis and/or therapy of viral diseases and/or carcinomas

The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid positioncompared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid positioncompared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating a human being affected by hypertension, and/or allergy and/or hair loss, and/or liability for infection.

CLCKb mutation as a diagnostic therapeutical target

Growing community of inventors

Tuebingen, Germany

Phillipp Lang